SecBot SecBot
SECBOTREPLAY Home › Report › LYEL

LYEL · Lyell Immunopharma announced upcoming presentations of ronde-cel Phase…

Lyell Immunopharma, Inc · PRESS-RELEASE filed Jun 4, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Jun 4, 2026 at 16:05 ET

Lyell Immunopharma announced upcoming presentations of ronde-cel Phase 1/2 safety and translational data at the EHA 2026 Congress, but no clinical results were disclosed. The company's key catalysts remain the PiNACLE trial data expected in H2 2026 and a potential BLA submission in 2027. This is a routine pipeline update with no immediate impact.

  • Ronde-cel safety and translational data to be presented at EHA 2026 (June 11-14).
  • PiNACLE trial (3L+ LBCL) data expected H2 2026, pivotal data by mid-2027, BLA submission 2027.
  • No new clinical data or financial guidance provided in this release.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access